Spondyloarthritis
Robert B Chao, MD
2 years ago
Another infusion option for axSpA!
INVIGORATE-1: Phase 3 RCT of IV Secukinumab in axSpA
Efficacious - ASAS40 response sustained thru 52 weeks
Safety profile similar to subq version
@RheumNow #ACR23 Abs#2545 https://t.co/biC8p3p6dl
Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated.
Janet Pope
2 years ago
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
Dr. Rachel Tate
2 years ago
Super interesting SpA phenotypical type world map. #ACR23 Abs #2195 continues to prove how heterogenous this disease is and the need for additional therapeutic agents for improved patient outcomes. https://t.co/hpKY7usUUb @rheumnow https://t.co/xJ1bx6wOC0
sheila
2 years ago
In this older grp of pts w/ chronic LBP, significant overlaps of deg & inflamm features on spinal imaging of DC, DISH & axSpA pts were seen
Also, +comorbids: HTN in DC; DM in DISH; smoking in axSpA
THM? DC & DISH are also axSpA mimics
#ACR23 ABST1862 @Rheumnow @rheumarhyme https://t.co/uNIwRchF1g
sheila
2 years ago
Will postpartum BME ⏩axSpA-like structural lesions?
Study by Varkas et al show there was no significant dev't of axSpA-like lesions on MRI in postpartum women 5 yrs after delivery.
Postpartum BME likely sec to transient mech stress-induced SI BME
#ACR23 ABST1892 @RheumNow https://t.co/KJ3DngmkbI
Robert B Chao, MD
2 years ago
Always refreshing to hear from another specialist's point of view
Cardiologist @Bweber04 on CVD and rheumatologic diseases
Increased risk of death, MI and HF exacerbation in our pt population
Increased all cause mortality
@RheumNow #ACR23 https://t.co/yOkPOmxU4N
Eric Dein
2 years ago
Later today at #ACR23 at 4pm
See Ab#2545 on IV secukinumab for AxSpA
Read about it now on @RheumNow:
https://t.co/s9IinpVxgR
Mike Putman EBRheum
2 years ago
Amazing & thoughtful poster re:protocol violates in TICOSPA trial
51.2% of pts violated T2T protocol at least once... but did not impact primary outcome
Good baseline for future "strategy" style pragmatic trials
@RheumNow #ACR23 #ACRBest Abstr2201 https://t.co/FhctgFNdNP
Eric Dein
2 years ago
CV Events in AS by Rx
A#L11 @RheumNow #ACR23
43K pts from Korean data
Rates of incident MI or CV:
18.7 per 10,000 py in non-bDMARD pt
8.9 in TNF
12.9 in IL-17
TNFi reduced risk of CVD HR 0.7, not signif for IL-17
Supports idea of TNFi giving a cardioprotective effect?
#ACRBest https://t.co/SvVVDSU23z
Dr. John Cush RheumNow
2 years ago
Real-World Issues in AxSpA: Treatment Intensification, Pregnancy
Dr. Rabab Nezam El-Din and colleagues explored patient- and disease-related determinants that were associated with treatment intensification among axSpA patients w/ high disease activity.
https://t.co/vZ66hsErBI https://t.co/pN8JZAEcqv
Dr. Rachel Tate
2 years ago
Be a SpA (and PsA) Sleuth! My article is your call to arms for better understanding and discovery of IBD in our inflammatory back pain patients. Consider fecal calprotectin AND robust ROS as your magnifying glass! #ACR23 @rheumnow https://t.co/OnQDEWgIWM
Dr. Rachel Tate
2 years ago
From patient to research/clinical rheumatologist and SpA advocate. Check out my #ACR23 interview with Dr. Hillary Norton. @DrHillaryNorton @RheumNow https://t.co/SeZeqb8wid
Poster Hall